Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MS treatment: postmarketing studies.

X Montalban1

  • 1EUI planta 2, Unitat de Neuroimmunología Clínica, Hospital Universitari Vall d'Hebron, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain. xavier.montalban@unic-em.com

Journal of the Neurological Sciences
|March 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthetic MRI in Progressive MS: Associations with Disability.

AJNR. American journal of neuroradiology·2025
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].

Revista de neurologia·2024
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)].

Revista de neurologia·2024
Same author

[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II)].

Revista de neurologia·2023
Same author

[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I)].

Revista de neurologia·2023
Same author

Validation of a New Semiautomated Segmentation Pipeline Based on the Spinal Cord Toolbox DeepSeg Algorithm to Estimate the Cervical Canal Area.

AJNR. American journal of neuroradiology·2023
Same journal

Distinguishing drug-target effects from natural lipid variation and incorporating imaging outcomes in Mendelian randomisation studies of multiple sclerosis.

Journal of the neurological sciences·2026
Same journal

Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study.

Journal of the neurological sciences·2026
Same journal

Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

Journal of the neurological sciences·2026
Same journal

Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

Journal of the neurological sciences·2026
Same journal

Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

Journal of the neurological sciences·2026
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
See all related articles

Multiple sclerosis (MS) treatment requires high patient adherence due to parenteral administration. Early identification of non-responsive patients is crucial for alternative therapeutic strategies.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
  • Current therapies aim to control disease activity but are administered parenterally, necessitating high patient adherence.
  • Close patient monitoring is vital for treatment adherence and management.

Purpose of the Study:

  • To highlight the importance of patient adherence in managing multiple sclerosis.
  • To discuss the comparative efficacy of registered MS drugs.
  • To emphasize the need for early identification of treatment non-responders.

Main Methods:

  • Review of existing literature on multiple sclerosis treatments.
  • Analysis of comparative studies (placebo-controlled and head-to-head).

Related Experiment Videos

  • Discussion of observational data regarding drug efficacy.

    • Main Results:

    • Multiple sclerosis drug efficacy has been compared against placebo, with varied results.
    • Observational and head-to-head studies show conflicting data on the comparative efficacy of different MS drugs.
    • A significant proportion of patients exhibit a lack of response to current treatments.

    Conclusions:

    • Effective management of multiple sclerosis requires sustained patient adherence to long-term parenteral therapies.
    • Identifying patients who do not respond to initial treatments is essential for timely therapeutic adjustments.
    • Further research may be needed to optimize treatment strategies and identify non-responders early.